8-KRegulation FDOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Regulation FD Disclosure (Apr 1, 2005)

Filed April 1, 2005For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) issued an 8-K filing on April 1, 2005, to update investors on significant developments concerning its multiple sclerosis drug, TYSABRI® (natalizumab). The company announced that a previously reported diagnosis of malignant astrocytoma in a patient in a Crohn's disease clinical study has been revised to progressive multifocal leukoencephalopathy (PML). This revised diagnosis, confirmed through an ongoing safety evaluation, is a critical development that directly impacts the understanding of TYSABRI's safety profile. As a direct consequence of this and the earlier voluntary suspension of TYSABRI marketing following safety concerns, Biogen Idec has withdrawn all previously issued financial guidance. Investors are strongly advised not to rely on any financial projections announced on February 7, 2005. This filing underscores the substantial uncertainty surrounding the future of TYSABRI and its potential financial impact on the company.

Key Highlights

  • 1Biogen Idec is revising its financial guidance and investors should no longer rely on previously issued projections from February 7, 2005.
  • 2The company and Elan are revising a previously reported diagnosis of malignant astrocytoma in a Crohn's disease clinical trial patient.
  • 3The revised diagnosis for the patient is progressive multifocal leukoencephalopathy (PML).
  • 4This revision is a result of an ongoing safety evaluation of TYSABRI (natalizumab).
  • 5The filing incorporates by reference a press release dated March 30, 2005, detailing these events.
  • 6This update follows the voluntary suspension of TYSABRI marketing announced on February 28, 2005.

Frequently Asked Questions

The company has withdrawn its financial guidance because of the ongoing safety evaluation of TYSABRI, specifically the revision of a patient diagnosis from malignant astrocytoma to progressive multifocal leukoencephalopathy (PML), and the prior voluntary suspension of TYSABRI's marketing.

Progressive multifocal leukoencephalopathy (PML) is a rare and serious opportunistic infection of the brain that affects the myelin sheath (the protective covering of nerve fibers) and can lead to severe disability or death. It is often associated with compromised immune systems.

Revising a diagnosis from malignant astrocytoma (a type of brain cancer) to PML indicates a shift in the understanding of a serious adverse event observed in a clinical trial. PML is a known, albeit rare, side effect associated with certain immune-modulating therapies, and its identification is crucial for assessing drug safety.

TYSABRI (natalizumab) is a medication developed by Biogen Idec and Elan for the treatment of multiple sclerosis. Its marketing was voluntarily suspended on February 28, 2005, due to safety concerns, including the occurrence of PML in patients.